Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rise Of The Biosimilar Formulary: CVS Excludes Lantus, Neupogen For 2017

Executive Summary

Zarxio and Basaglar will be the beneficiaries of the cost-cutting move, although how much it will help the follow-on products remains unclear.

Advertisement

Related Content

3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Biosimilar Launch Notification Delay Remains In The US, Might Not Matter For Newer Products
FDA Makes It Official With Basaglar Approval For Diabetes
Zarxio 15% Price Discount To Neupogen In US Tracks European Strategy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097053

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel